Screener
Maze Therapeutics MAZE Debt Issuance Proceeds
Debt Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Maze Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfDebt.
The source filing: Maze Therapeutics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:11 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219430
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Purchases of property and equipment | (93) | (299) |
| Net cash provided by (used) in investing activities | 6,275 | (299) |
| Financing activities | ||
| Proceeds from debt issuance, net | 39,401 | — |
| Payment of debt issuance costs | (886) | — |
| Proceeds from exercise of stock option awards | 4,079 | 126 |
| Payment of deferred offering costs | (226) | — |
| Payment of offering costs for private placement | (11) | — |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Maze Therapeutics's debt issuance proceeds?
- Maze Therapeutics (MAZE) reported debt issuance proceeds of $39.4M in Q1 2026.
- What does debt issuance proceeds mean?
- Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.
Ask your AI about Maze Therapeutics's debt issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude